NRIX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Nurix Therapeutics Inc (NRIX) is not a strong buy for a beginner investor with a long-term strategy at this time. While the company has potential catalysts in its pipeline and a bullish technical setup, its worsening financial health, missed earnings expectations, and lack of significant trading or political interest make it a less compelling investment currently. Holding off for clearer signs of financial improvement or stronger catalysts is advisable.
The technical indicators show a bullish trend with the MACD histogram positively expanding, RSI in the neutral zone, and moving averages indicating upward momentum (SMA_5 > SMA_20 > SMA_200). Key resistance levels are at 16.776 and 17.432, while support levels are at 14.652 and 13.996.
Analysts maintain optimistic long-term ratings, with potential upside catalysts in 2026 and 2027.
Nurix reported a Q1 net loss of $87.2 million and a revenue decline to $6.3 million, missing expectations. The company faces ongoing profitability pressures, and hedge funds and insiders show neutral sentiment with no significant trading activity.
In Q1 2026, the company reported a net loss of $87.2 million and revenue of $6.3 million, reflecting worsening financial health. In Q4 2025, revenue increased 2.21% YoY, net income improved 33.60% YoY, and EPS rose 9.33% YoY, but the company remains unprofitable.
Analysts have lowered price targets slightly but maintain Buy or Overweight ratings, citing undervaluation and potential long-term catalysts. The average price target remains significantly above the current price, indicating potential upside.
